Challenges in assessing microbial susceptibility and predicting clinical response to newer-generation fluoroquinolones

Journal of Ocular Pharmacology and Therapeutics

Volumn 28, Issue 1, 2012, Pages 3-11

  Segreti, John ^a   Jones, Ronald N ^b   Bertino, Joseph S ^c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b JMI LABORATORIES   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BESIFLOXACIN; CEFTRIAXONE; CIPROFLOXACIN; GATIFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN;

ANTIBIOTIC SENSITIVITY; BACTERIAL EYE INFECTION; BACTERICIDAL ACTIVITY; CONJUNCTIVITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTOXICATION; DRUG METABOLISM; DRUG RESEARCH; HAEMOPHILUS INFLUENZAE; HUMAN; IN VITRO STUDY; KERATITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, OPHTHALMIC; ANIMALS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; AZEPINES; BACTERIA; BACTERIAL INFECTIONS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; QUINOLINES;

EID: 84863129497     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0072     Document Type: Review

References (64)

1. Egger, S.F., Ruckhofer, J., Alzner, E., et al. In vitro susceptibilities to topical antibiotics of bacteria isolated from the surface of clinically symptomatic eyes. Ophthalmic. Res. 33:117-120, 2001. (Pubitemid 32221233)
2. Mah, F.S. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Curr. Opin. Ophthalmol. 15:316-320, 2004. (Pubitemid 38962111)
3. Haas, W., Pillar, C.M., Zurenko, G.E., et al. Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 53:3552-3560, 2009.
4. Mittmann, N., Jivarj, F., Wong, A., et al. Oral fluor-oquinolones in the treatment of pneumonia, bronchitis and sinusitis. Can. J. Infect. Dis.13:293-300, 2002. (Pubitemid 35402898)
5. Schaeffer, A.J. The expanding role of fluoroquinolones. Dis. Mon. 49:129-147, 2003. (Pubitemid 36350780)
6. Jafri, H.S., and McCracken G.H., Jr. Fluoroquinolones in paediatrics. Drugs 58(suppl 2):43-48, 1999. (Pubitemid 29500084)
7. Blondeau, J.M. The role of fluoroquinolones in skin and skin structure infections. Am. J. Clin. Dermatol. 3:37-46, 2002. (Pubitemid 34158101)
8. Mouton, J.W. Breakpoints: current practice and future perspectives. Int. J. Antimicrob. Agents 19:323-331, 2002. (Pubitemid 34308979)
9. Turnidge, J., and Paterson, D.L. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408, 2007. (Pubitemid 47175010)
10. Kowalski, R.P., Yates, K.A., Romanowski, E.G., et al. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data. Ophthalmology 112:1987-1991, 2005.
11. European Committee on Antimicrobial Susceptibility Testing (EUCAST). Clinical Breakpoints. Available at www.eucast.org/clinical-breakpoints (accessed July 11, 2011).
12. Clinical and Laboratory Standards Institute (CLSI). Development of In Vitro Susceptibility Testing Criteria and Quality Control Parameters; Approved Guideline-Third Edition. CLSI Document M23-A2. Wayne, PA: Clinical and Laboratory Standards Institute; 2001.
13. Liu, P., Muller, M., and Derendorf, H. Rational dosing of antibiotics: the use of plasma concentrations versus time concentrations. Int. J. Antimicrob. Agents 19:285-290, 2002. (Pubitemid 34308976)
14. Booker, B.M., Smith, P.F., Forrest, A., et al. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob. Agents Chemother. 49:1775-1781, 2005. (Pubitemid 40631588)
15. Forrest, A., Nix, D.E., Ballow, C.H., et al. Pharmacody-namics of intravenous ciprofloxacin in seriously ill patients. Antimicrob. Agents Chemother. 37:1073-1081, 1993. (Pubitemid 23141323)
16. Drusano, G.L., Preston, S.L., Fowler, C., et al. Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189:1590-1597, 2004. (Pubitemid 38648286)
17. Eagle, H., Fleischman, R., and Levy, M. Continuous versus discontinuous therapy with penicillin: the effect of interval between injections on therapeutic efficacy. N. Engl. J. Med. 248:481-488, 1953.
18. Vogelman, B., Gudmundsson, S., Leggett, J., et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847, 1988.
19. Leggett, J.E., Fantin, B., Ebert, S., et al. Comparative antibiotic dose-effect relations at several dosing intervals in mu-rine pneumonitis and thigh-infection models. J. Infect. Dis. 159:281-282, 1989.
20. Slavik, R.S., and Jewesson, P.J. Selecting antibacterials for outpatient parenteral antimicrobial therapy: pharmacoki-netic-pharmacodynamic considerations. Clin. Pharmacokinet. 42:793-817, 2003. (Pubitemid 36995082)
21. Ambrose, P.G., Bhavnani, S.M., Rubino, C.M., et al. Phar-macokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86, 2007. (Pubitemid 44968990)
22. Jumbe, N., Louie, A., Leary, R., et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J. Clin. Invest. 112:275-285, 2003. (Pubitemid 38056363)
23. Scaglione, F., Mouton, J.W., and Mattina, R. Pharmacody-namics of levofloxacin in a murine pneumonia model: importance of peak to MIC ratio versus AUC. In: Interscience Conference of Antimicrobial Agents Chemotherapy. San Francisco, CA: American Society of Microbiology; 1999; p. 6.
24. Wright, D.H., Brown, G.H., Peterson, M.L., et al. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Che-mother. 46:669-683, 2000.
25. Allen, G.P., Kaatz, G.W., and Rybak, M.J. In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a phar-macodynamic model. Int. J. Antimicrob. Agents 24:150-160, 2004. (Pubitemid 38993694)
26. Metzler, K., Hansen, G.M., Hedlin, P., et al. Comparison of minimal inhibitory and mutant prevention drug concentrations of 4 fluoroquinolones against clinical isolates of methicillin-susceptible and -resistant Staphylococcus aureus. Int. J. Antimicrob. Agents 24:161-167, 2004. (Pubitemid 38993695)
27. Martin, E., Koup, J.R., Paravicini, U., et al. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J. Pediatr. 105:475-481, 1984. (Pubitemid 14072140)
28. Robertson, S.M., Curtis, M.A., Schlech, B.A., et al. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv. Ophthalmol. 50(suppl 1):S32-S45, 2005. (Pubitemid 41657597)
29. Wagner, R.S., Abelson, M.B., Shapiro, A., et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and le-vofloxacin concentrations in human conjunctival tissue. Arch. Ophthalmol. 123:1282-1283, 2005. (Pubitemid 41316756)
30. Aihara, M., Miyanaga, M., Minami, K., et al. A comparison of fluoroquinolone penetration into human conjunctival tissue. J. Ocul. Pharmacol. Ther. 24:587-591, 2008.
31. Avelox [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals Inc.; 2008.
32. Levaquin [package insert]. Raritan NJ: Ortho-McNeil-Janssen Pharmaceuticals Inc; 2009.
33. Proksch, J.W., Granvil, C.P., Siou-Mermet, R., et al. Ocular pharmacokinetics of besifloxacin following topical administration to rabbits, monkeys, and humans. J. Ocul. Pharmacol. Ther. 25:335-344, 2009.
34. Torkildsen, G., Proksch, J.W., Shapiro, A., et al. Concentrations of besifloxacin, gatifloxacin, and moxifloxacin in human conjunctiva after topical ocular administration. Clin. Ophthalmol. 4:1-11, 2010.
35. Proksch, J., and Ward, K. Ocular pharmacokinetics/phar-macodynamics of besifloxacin, moxifloxacin and gatifloxacin following topical administration to pigmented rabbits. J. Ocul. Pharmacol. Ther. 26:449-458, 2010.
36. Owen, G.R., Brooks, A.C., James, O., et al. A novel in vivo rabbit model that mimics human dosing to determine the distribution of antibiotics in ocular tissues. J. Ocul. Pharmacol. Ther. 23:335-342, 2007. (Pubitemid 350195057)
37. Holland, E.J., Lane, S., Kim, T., et al. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxi-floxacin 0.5% ophthalmic solutions after keratoplasty. Cornea 27:314-319, 2008. (Pubitemid 351440866)
38. Fukuda, M., and Sasaki, H. Measurement of AQCmax of five different ophthalmic solutions and discussion of its new application. J. Ocul. Pharmacol. Ther. 25:351-356, 2009.
39. Sugioka, K., Fukuda, M., Komoto, S., et al. Intraocular penetration of sequentially instilled topical moxifloxacin, gatifloxacin, and levofloxacin. Clin. Ophthalmol. 3:553-557, 2009.
40. Ong-Tone, L. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery. J. Cataract. Refract. Surg. 33:59-62, 2007. (Pubitemid 46001538)
41. Ward, K.W., Lepage, J.F., and Driot, J.Y. Nonclinical phar-macodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. J. Ocul. Pharmacol. Ther. 23:243-256, 2007. (Pubitemid 46986605)
42. Yoshida, J., Kim, A., Pratzer, K.A., et al. Aqueous penetration of moxifloxacin 0.5% ophthalmic solution and besifloxacin 0.6% ophthalmic suspension in cataract surgery patients. J. Cataract. Refract. Surg. 36:1499-1502, 2010.
43. Donnenfeld, E.D., Comstock, T.L., and Proksch, J.W. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application. J. Cataract. Refract. Surg. 37:1082-1089, 2011.
44. Westermeyer, H.D., Hendrix, D.V., Ward, D.A., and Cox, S.K. Tear, cornea, and aqueous humor concentrations of ci-profloxacin and moxifloxacin after topical ocular application in ophthalmologically normal horses. Am. J. Vet. Res. 72:398-403, 2011.
45. Lichtenstein, S.J., Wagner, R.S., Jamison, T., et al. Speed of bacterial kill with a fluoroquinolone compared with non-fluoroquinolones: clinical implications and a review of kinetics of kill studies. Adv. Ther. 24:1098-1111, 2007. (Pubitemid 350274789)
46. Callegan, M.C., Novosad, B.D., Ramadan, R.T., et al. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones. Adv. Ther. 26:447-454, 2009.
47. Haas, W., Pillar, C.M., Hesje, C.K., et al. Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumo-niae and Haemophilus influenzae. J. Antimicrob. Chemother. 65:1441-1447, 2010.
48. Tepedino, M.E., Heller, W.H., Usner, D.W., et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr. Med. Res. Opin. 25:1159-1169, 2009.
49. Karpecki, P., DePaolis, M., Hunter, J.A., et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin. Ther. 31:514-526, 2009.
50. McDonald, M.B., Protzko, E.E., Brunner, L.S., et al. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. Ophthalmology 116:1615-1623, 2009.
51. Silverstein, B.E., Allaire, C., Bateman, K.M., et al. Efficacy and tolerability of besifloxacin 0.6% ophthalmic suspension administered twice daily for three days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children. Clin. Ther. 33:13-26, 2011.
52. Protzko, E., Bowman, L., Abelson, M., et al. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mu-coadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis. Invest. Ophthalmol. Vis. Sci. 48:3425-3429, 2007. (Pubitemid 351261073)
53. McDonald, M., and Blondeau, J. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J. Cataract. Refract. Surg. 36:1588-1598, 2010.
54. Bertino, J. Impact of antibiotic resistance in the management of ocular infections: the role of current and future antibiotics. Clin. Ophthalmol. 3:507-521, 2009.
55. Raizman, M.B., Rubin, J.M., Graves, A.L., et al. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers. Clin. Ther. 24:1439-1450, 2002. (Pubitemid 35176975)
56. Bucci, F.A., Jr. An in vivo study comparing the ocular absorption of levofloxacin and ciprofloxacin prior to phacoe-mulsification. Am. J. Ophthalmol. 37:308-312, 2004. (Pubitemid 38221005)
57. Sundelin, K., Seal, D., Gardner, S., et al. Increased anterior chamber penetration of topical levofloxacin 0.5% after pulsed dosing in cataract patients. Acta Ophthalmol. 87:160-165, 2009.
58. Solomon, R., Donnenfeld, E.D., Perry, H.D., et al. Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor. Ophthalmology 112:466-469, 2005. (Pubitemid 40312502)
59. McCulley, J.P., Caudle, D., Aronowicz, J.D., et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology 113:955-959, 2006. (Pubitemid 43795230)
60. Clode, A.B., Davis, J.L., Salmon, J., et al. Aqueous humor and plasma concentrations of ciprofloxacin and moxi-floxacin following topical ocular administration in ophthal-mologically normal horses. Am. J. Vet. Res. 71:564-569, 2010.
61. Presterl, E., Mueller-Uri, P., Grisold, A., et al. Ciprofloxacin-and methicillin-resistant Staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid. Eur. J. Clin. Microbiol. Infect. Dis. 20:486-489, 2001. (Pubitemid 34212110)
62. Wilhelmus, K.R., Abshire, R.L., and Schlech, B.A. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch. Ophthal-mol. 121:1229-1233, 2003. (Pubitemid 37128399)
63. Parmar, S. Comparison of topical gatifloxacin 0.3% and ci-profloxacin 0.3% for the treatment of bacterial keratitis. Am. J. Ophthalmol. 2:282-286, 2006.
64. Kaye, S., Tuft, S., Neal, T., et al. Bacterial susceptibility to topical antimicrobials and clinical outcome in bacterial ker-atitis. Invest. Ophthalmol. Vis. Sci. 51:362-368, 2010.